Drug Trial Radar · NCT03920228
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Apr 1, 2019
Primary completion
Sep 19, 2020
Study completion Oct 19, 2020
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.
Conditions
- Pachyonychia Congenita
Interventions
PTX-022Drug
PTX-022 QTORIN
PlaceboDrug
Placebo topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Global Assessment of Activities ScaleTime frame: 6 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Arizona Research Center
Phoenix, Arizona
Stanford University
Palo Alto, California
Yale University
New Haven, Connecticut
International Dermatology Research
Miami, Florida
Northwestern University
Chicago, Illinois
Minnesota Clinical Study Center
Fridley, Minnesota
Oregon Health and Science University
Portland, Oregon
Paddington Testing Co.
Philadelphia, Pennsylvania
University of Utah
Murray, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.